NYSE:CBT - US1270551013 - Common Stock
The current stock price of CBT is 82.94 USD. In the past month the price increased by 8.95%. In the past year, price decreased by -20.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LYB | LYONDELLBASELL INDU-CL A | 16.42 | 18.89B | ||
DOW | DOW INC | 358.71 | 17.80B | ||
WLK | WESTLAKE CORP | 84.67 | 11.62B | ||
HWKN | HAWKINS INC | 41.88 | 3.55B | ||
MEOH | METHANEX CORP | 7.64 | 2.79B | ||
OLN | OLIN CORP | 178.23 | 2.66B | ||
PCT | PURECYCLE TECHNOLOGIES INC | N/A | 2.34B | ||
BAK | BRASKEM SA-CLASS A- ADR | N/A | 1.27B | ||
WLKP | WESTLAKE CHEMICAL PARTNERS L | 14.87 | 780.57M | ||
KRO | KRONOS WORLDWIDE INC | 323.5 | 744.31M | ||
MATV | MATIV HOLDINGS INC | 27.76 | 682.33M | ||
TROX | TRONOX HOLDINGS PLC | N/A | 660.78M |
Cabot Corp. is a global specialty chemicals and performance materials company. The company is headquartered in Boston, Massachusetts and currently employs 4,200 full-time employees. The firm's principal products are reinforcing and specialty carbons, specialty compounds, conductive additives, carbon nanotubes, fumed metal oxides, inkjet colorants and aerogel. The company operates through two segments: Reinforcement Materials and Performance Chemicals. Its reinforcing carbon products are used in tires and industrial products. In addition to its reinforcing carbons, it manufactures engineered elastomer composites (E2C) solutions that are composites of reinforcing carbons and rubber made using its patented elastomer composites manufacturing process. Under Performance Chemicals segment, it designs, manufactures and sells materials that deliver performance in a range of customer applications across the automotive, construction, infrastructure, inkjet printing, electronics, and consumer products sectors and in applications related to the generation, transmission and storage of energy.
CABOT CORP
Two Seaport Lane Suite 1400
Boston MASSACHUSETTS 02210 US
CEO: Sean D. Keohane
Employees: 4200
Phone: 16173450100
The current stock price of CBT is 82.94 USD. The price increased by 4.85% in the last trading session.
The exchange symbol of CABOT CORP is CBT and it is listed on the New York Stock Exchange, Inc. exchange.
CBT stock is listed on the New York Stock Exchange, Inc. exchange.
9 analysts have analysed CBT and the average price target is 87.47 USD. This implies a price increase of 5.46% is expected in the next year compared to the current price of 82.94. Check the CABOT CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CABOT CORP (CBT) has a market capitalization of 4.46B USD. This makes CBT a Mid Cap stock.
CABOT CORP (CBT) currently has 4200 employees.
CABOT CORP (CBT) has a support level at 77.63 and a resistance level at 82.95. Check the full technical report for a detailed analysis of CBT support and resistance levels.
The Revenue of CABOT CORP (CBT) is expected to decline by -4.72% in the next year. Check the estimates tab for more information on the CBT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CABOT CORP (CBT) has a dividend yield of 2.27%. The yearly dividend amount is currently 1.7. Check the full fundamental report for a detailed analysis of CBT dividend history, reliability and sustainability.
CABOT CORP (CBT) will report earnings on 2025-11-03, after the market close.
The PE ratio for CABOT CORP (CBT) is 11.27. This is based on the reported non-GAAP earnings per share of 7.36 and the current share price of 82.94 USD. Check the full fundamental report for a full analysis of the valuation metrics for CBT.
The outstanding short interest for CABOT CORP (CBT) is 4.1% of its float. Check the ownership tab for more information on the CBT short interest.
ChartMill assigns a technical rating of 5 / 10 to CBT. When comparing the yearly performance of all stocks, CBT is a bad performer in the overall market: 78.46% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to CBT. CBT scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months CBT reported a non-GAAP Earnings per Share(EPS) of 7.36. The EPS increased by 6.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 10.96% | ||
ROA | 10.89% | ||
ROE | 27.13% | ||
Debt/Equity | 0.78 |
9 analysts have analysed CBT and the average price target is 87.47 USD. This implies a price increase of 5.46% is expected in the next year compared to the current price of 82.94.
For the next year, analysts expect an EPS growth of 4.29% and a revenue growth -4.72% for CBT